| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| ArriVent BioPharma Inc. | Furmonertinib - (FURVENT) | 1L advanced or metastatic NSCLC with EGFR exon 20 insertion mutations | Phase 3 | Ongoing | Oral | Oncology |
| Arrowhead Pharmaceuticals Inc. | Olpasiran (AMG 890) - (OCEAN(a)-DOSE) | Cardiovascular disease / Elevated Lipoprotein | Phase 3 | Trial Planned | Subcutaneous | Cardiology |
| Arrowhead Pharmaceuticals Inc. | Fazirsiran (TAK-999/ARO-AAT) - (REDWOOD) | Alpha-1 antitrypsin deficiency (AATD-LD) | NDA Filing | Data Released | Intravenous | Genetic Disorder |
| Arrowhead Pharmaceuticals Inc. | Plozasiran (ARO-APOC3) - (CAPITAN) | Mixed hyperlipidemia | Phase 3 | Trial Planned | Subcutaneous | Cardiology |
| Arrowhead Pharmaceuticals Inc. | Plozasiran (ARO-APOC3) - (CAPITAN) | Mixed hyperlipidemia | Phase 3 | Trial Planned | Subcutaneous | Cardiology |
| Arrowhead Pharmaceuticals Inc. | Fazirsiran (ARO-AAT) - (SEQUOIA) | Alpha-1 Liver Disease | Phase 2/3 | Ongoing | Subcutaneous | Genetic Disorder |
| Arrowhead Pharmaceuticals Inc. | Olpasiran (AMG 890) - (OCEAN(a)-DOSE) | Cardiovascular disease / Elevated Lipoprotein | Phase 3 | Trial Planned | Subcutaneous | Cardiology |
| Arrowhead Pharmaceuticals Inc. | Plozasiran (ARO-APOC3) - (CAPITAN) | Mixed hyperlipidemia | Phase 3 | Trial Planned | Subcutaneous | Cardiology |